Active Filter(s):
Details:
ANEW intends to use the proceeds from the transaction to progress its lead gene therapy programs including, Alpha Klotho-based gene therapy being developed for the treatment of amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD).
Lead Product(s): Alpha Klotho-based Gene Therapy
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Redwoods Acquisition Corp.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger May 30, 2023